BWAY
BrainsWay Ltd.
$12.03
+0.33% 2026-10-20
Healthcare
BWAYSPY
1W
+0.9%
1M
-11.6%
3M
-25.5%
6M
-21.5%
YTD
+26.5%
1Y
+51.6%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsBrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
GlobeNewswire · Oct 19
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
GlobeNewswire · Oct 13
BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore
Insider Monkey · Sep 10
Are Options Traders Betting on a Big Move in Brainsway Stock?
Zacks · Sep 09
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
GlobeNewswire · Sep 08
Key stats
Market cap$484.2M
P/E (trailing)52.3
P/E (forward)23.7
52-week range7.13 – 17.40
Revenue growth (YoY, latest qtr)+35.4%
Dividend yield0.00%
Analyst consensusStrong Buy (3)
Mean price target$19.27 (+60%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-10 · before open · EPS est 0.09
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | 0.07 | 0.07 | -4.5% |
| 2026-05-13 | 0.05 | 0.06 | +20.0% |
| 2026-03-11 | 0.03 | 0.06 | +155.4% |
| 2025-11-11 | 0.02 | 0.02 | -14.3% |
| 2025-08-13 | 0.02 | 0.03 | +53.8% |
| 2025-05-13 | 0.01 | 0.01 | -14.3% |
| 2025-03-11 | 0.01 | 0.02 | +100.0% |
| 2024-11-12 | 0.01 | 0.01 | +100.0% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $17.1M | +35.4% |
| 2026-03-31 | $15.5M | – |
| 2025-12-31 | $14.5M | – |
| 2025-09-30 | $13.5M | – |
| 2025-06-30 | $12.6M | – |
Analyst actions
HC Wainwright & Co.
PT $19
2026-10-19 · reit
Buy → BuyPT $19
BTIG
PT $20
2026-09-10 · reit
Buy → BuyPT $20
HC Wainwright & Co.
PT $19
2026-09-08 · reit
Buy → BuyPT $19
HC Wainwright & Co.
PT $19
2026-08-31 · main
Buy → BuyPT $19
Ladenburg Thalmann
PT $19
2026-08-13 · main
Buy → BuyPT $19
BTIG
PT $20
2026-08-12 · main
Buy → BuyPT $20
Stats refreshed 2026-10-20 18:14:13 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.